AGuIX纳米颗粒联合放疗和替莫唑胺治疗新诊断胶质母细胞瘤的NANO-GBM试验:1b期结果与基于MRI的生物分布
NANO-GBM 1b/2R期试验的1b期部分首次在人体中将静脉钆基诊疗纳米颗粒AGuIX与放疗和替莫唑胺联合用于新诊断胶质母细胞瘤。2022年3月至2023年3月入组8例患者,剂量递增至100 mg/kg,仅1例出现剂量限制性毒性(3级淋巴细胞减少,与替莫唑胺相关),确定RP2D为100 mg/kg,AGuIX平均AUC随剂量增加,纳米颗粒在GBM中广泛分布。
要点
- AGuIX推荐2期剂量(RP2D)确定为100 mg/kg,共4次注射。
- 仅1例患者出现剂量限制性毒性:3级淋巴细胞减少,与替莫唑胺相关。
- AGuIX平均AUC随剂量增加,纳米颗粒在GBM中广泛分布。
核心结论
- 结果证实AGuIX无相关毒性,且纳米颗粒在胶质母细胞瘤中广泛分布,支持以RP2D 100 mg/kg(4次注射)推进至随机2期部分。
研究设计与样本
- NANO-GBM为1b/2R期试验(NCT04881032),本文报告1b期部分,采用时间-事件持续重评估方法进行剂量递增,设50、75和100 mg/kg三个剂量水平。
- 入组标准为18至75岁、新诊断且组织学确诊的胶质母细胞瘤、切除不完全(活检或部分手术)的患者。
- 患者接受放疗(60 Gy)、同步和辅助替莫唑胺,以及4次AGuIX注射(D-3/-7、D1、D8和D15)。
- 剂量限制性毒性定义为任何3-4级不良事件(CTCAE v5.0),除外脱发、恶心和快速控制的呕吐。
- 评估了药代动力学和基于MRI的生物分布。
主要发现
- 2022年3月至2023年3月共入组8例患者:50 mg/kg组1例,75 mg/kg组1例,100 mg/kg组6例。
- 所有患者均接受了4次AGuIX注射。
- 仅1例患者(100 mg/kg组)出现剂量限制性毒性:3级淋巴细胞减少(与替莫唑胺相关)。
- AGuIX平均AUC随剂量增加。
- AGuIX浓度中等(36-123 µM)和高(123-291 µM)或极高(>291 µM)的GBM区域平均分别占38.7%和26.8%。
关键数值与推荐
- AGuIX的RP2D确定为100 mg/kg。
- 剂量限制性毒性定义为任何3-4级不良事件(CTCAE v5.0),除外脱发、恶心和快速控制的呕吐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In glioblastoma (GBM), tumor progression occurs mainly within the irradiated tumor volume. To address this challenge, a radiosensitization strategy with intravenous gadolinium-based theranostic nanoparticles (AGuIX) is being explored in the NANO-GBM phase1b/2R trial (NCT04881032). Here, we present the results of the phase 1b part, which is the first-in-human use of these nanoparticles with radiotherapy and chemotherapy for the treatment of newly diagnosed GBM. MATERIAL AND METHODS: Eligible patients were aged 18 to 75 years with newly diagnosed and histologically confirmed GBM, with incomplete resection (biopsy or partial surgery). The phase 1b part was a dose escalation approach (Time-to-event Continuous Reassessment Method) with three dose levels: 50, 75, and 100 mg/kg. Patients were treated with RT (60 Gy), and concomitant and adjuvant TMZ, and 4 injections of AGuIX (D-3/-7, D1, D8, and D15). Dose-limiting-toxicity (DLT) was defined as any grade 3-4 adverse event (CTCAE v5.0), excluding alopecia, nausea, and rapidly controlled vomiting. Pharmacokinetic (PK), and biodistribution based on MRI were evaluated. RESULTS: Between March 2022 and March 2023, eight patients were enrolled: 1 at 50 mg/kg, 1 at 75 mg/kg, and 6 at 100 mg/kg. All patients received the four AGuIX injections. Only one patient experienced a DLT (at 100 mg/kg): a grade 3 lymphopenia (related to TMZ). The RP2D of AGuIX was determined as 100 mg/kg. AGuIX mean AUC increased with dose. Regions of GBM with moderate (36-123 µM), and high (123-291 µM) or very high (>291 µM) AGuIX concentrations accounted in average for 38.7 and 26.8 %, respectively. CONCLUSION: These results confirm the lack of AGuIX-related toxicity and the widespread dispersion of nanoparticles throughout GBM. This supports progression to the randomized phase 2 part, utilizing an RP2D of AGuIX of 100 mg/kg (4 injections).
引用
- Biau J, Durando X, Boux F, et al. NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution. Clin Transl Radiat Oncol. 2024. PMID: 39184998. doi:10.1016/j.ctro.2024.100833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。